Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1801MR)

This product GTTS-WQ1801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1801MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2231MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ15599MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ15329MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ7819MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ2389MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ13393MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ14426MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW